CARY, N.C., Sept. 25, 2025 – Biologics by McKesson, in partnership with Inspirogene by McKesson, has been chosen by Precigen to be the exclusive specialty pharmacy for their newly approved novel immunotherapy to treat adults with recurrent respiratory papillomatosis (RRP).
This therapy is approved for the treatment of adults with recurrent respiratory papillomatosis (RRP) – a rare and devastating chronic disease that affects the upper and lower respiratory tracts. Until now, patients have had few options beyond repeated surgeries. This therapy offers a new path forward for RRP patients.
Read the full McKesson press release: HERE